Phase 1/2 × Leukemia, Lymphocytic, Chronic, B-Cell × Immunotherapy, Adoptive × Clear all
NCT03277729 2026-01-05

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Fred Hutchinson Cancer Center

Phase 1/2 Active not recruiting
53 enrolled 11 charts